The expression of CD146 predicts a poor overall survival in patients with adenocarcinoma of the lung.

@article{Oka2012TheEO,
  title={The expression of CD146 predicts a poor overall survival in patients with adenocarcinoma of the lung.},
  author={Soichi Oka and Hidetaka Uramoto and Yasuhiro Chikaishi and Fumihiro Tanaka},
  journal={Anticancer research},
  year={2012},
  volume={32 3},
  pages={861-4}
}
BACKGROUND The epithelial-mesenchymal transition (EMT) is also involved in cancer progression and metastasis. The expression of mesenchymal marker genes might be associated with a more aggressive form of the disease. CD146 is a marker of mesenchymal cells, a potentially metastasis-promoting cell adhesion molecule, and its expression has been described in various types of solid tumors. We, herein, evaluated the expression of CD146 in patients with adenocarcinoma of the lung by using… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

CD146 promotes metastasis and predicts poor prognosis of hepatocellular carcinoma.

Journal of experimental & clinical cancer research : CR • 2016

Does smoking, age or gender affect the protein phenotype of extracellular vesicles in plasma?

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis • 2016

ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer

European Journal of Nuclear Medicine and Molecular Imaging • 2016
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 20 references

Global cancer statistics.

CA: a cancer journal for clinicians • 2011

Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2010

Phase II trial of adjuvant chemotherapy with bi - weekly carboplatin plus paclitaxel in patients with completely resected non - small cell lung cancer

T Yamashita, H Uramoto, +7 authors K Yasumoto
Anticancer Res • 2010

Similar Papers

Loading similar papers…